Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors-Reference-Cited by-同舟云学术

Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors

Published:2017-05-08 Issue:2 Volume:46 Page:150-161
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Ward M. G.¹²³^ORCID,Warner B.¹,Unsworth N.⁴,Chuah S.-W.⁵,Brownclarke C.¹,Shieh S.⁵,Parkes M.⁵,Sanderson J. D.¹,Arkir Z.⁴,Reynolds J.³,Gibson P. R.²³,Irving P. M.¹

Affiliation:

1. Department of Gastroenterology; Guy's and St. Thomas’ NHS Foundation Trust; London UK

2. Department of Gastroenterology; Alfred Hospital; Melbourne Victoria Australia

3. Faculty of Medicine, Nursing and Health Sciences; Monash University; Melbourne Victoria Australia

4. Reference Chemistry, Viapath; St. Thomas’ Hospital; London UK

5. Department of Medicine; Addenbrooke's Hospital; University of Cambridge; Cambridge UK

Funder

ForCrohn's UK Charity Group

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14124/fullpdf

Reference59 articles.

1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

2. Infliximab maintenance therapy for fistulizing Crohn's disease;Sands;N Engl J Med,2004

3. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006

4. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial;Sandborn;Gut,2007

5. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients;Baert;J Crohn's Colitis,2013

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022;Frontiers in Pharmacology;2024-07-08

3. Evaluation of infliximab-induced genotoxicity and possible action on BCL-2 and P53 genes;Journal of Toxicology and Environmental Health, Part A;2024-06-26

4. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease;Therapeutic Advances in Gastroenterology;2024-01

5. The perceived waning of biologics in severe asthma;Respiratory Medicine;2023-11